Regeneron Pharmaceuticals (REGN) was evaluated by Validea's Benjamin Graham-based deep value model, scoring 71%. This rating falls short of the 80% threshold signifying 'some interest' for the strategy, primarily because REGN failed the P/E and Price/Book ratio criteria, indicating its current valuation does not align with the model's strict deep value parameters, despite passing fundamental tests for sales, long-term EPS growth, and debt levels.
Regeneron Pharmaceuticals (REGN) receives a mixed evaluation from Validea's Benjamin Graham-inspired deep value model, scoring 71%, which falls short of the 80% threshold that would signal active interest from the strategy. The analysis reveals a dichotomy between the company's fundamental strength and its current market valuation. REGN successfully passes criteria related to its operational health, including sales, current ratio, long-term EPS growth, and a manageable debt level relative to net current assets. However, it fails on the two key valuation metrics central to the Graham methodology: the Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios. This indicates that while the company is fundamentally sound and exhibits solid long-term growth, its stock price is too high to qualify as a classic deep value investment, aligning with its classification as a large-cap growth stock which typically commands richer multiples.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
